Sign in to view content

Evaluating Intravitreal ANX007, a Novel C1q Inhibitor, in the Treatment of GA Secondary to AMD: The ARCHER Study

David S. Boyer, MD

Video
Published 2021

Related

Phase 3 Randomized, Double-Masked Studies of Brolucizumab Versus Aflibercept in nAMD: Expanded Primary and Secondary Outcomes From HAWK/HARRIER
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2018
The OASIS Trial: Natural History of Symptomatic Vitreomacular Adhesion
Joseph M. Coney, MD, FASRS
Annual Meeting Talks
2016
Future DME Therapeutics
Updates from the Field
2017

Category: AMD-Non-Neovascular

See more